Li Sun1,2, Rui Song1,3,4, Ying Chen1,3,4, Ri-fang Yang1,3,4, Ning Wu1,3,4, Rui-bin Su1,3,4, Jin Li1,3,4. 1. Department of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. 2. Department of Anesthesiology, General Hospital of Beijing Military Command, Beijing 100700, China. 3. State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China. 4. Beijing Key Laboratory of Neuropsychopharmacology, Beijing 100850, China.
Abstract
AIM: We have reported that a selective dopamine D3 receptor antagonist YQA14 attenuates cocaine reward and relapse to drug-seeking in mice. In the present study, we investigated whether YQA14 could inhibit methamphetamine (METH)-induced locomotor sensitization and conditioned place preference (CPP) in mice. METHODS: Locomotor activity was monitored in mice treated with METH (1 mg/kg, ip) daily on d 4-13, followed by a challenge with METH (0.5 mg/kg) on d 21. CPP was examined in mice that were administered METH (1 mg/kg) or saline alternately on each other day for 8 days (METH conditioning). YQA14 was injected intraperitoneally 20 min prior to METH or saline. RESULTS: Both repetitive (daily on d 4-13) and a single injection (on the day of challenge) of YQA14 (6.25, 12.5 and 25 mg/kg) dose-dependently inhibited the acquisition and expression of METH-induced locomotor sensitization. However, repetitive injection of YQA14 (daily during the METH conditioning) did not alter the acquisition of METH-induced CPP, whereas a single injection of YQA14 (prior to CPP test) dose-dependently attenuated the expression of METH-induced CPP. In addition, the repetitive injection of YQA14 dose-dependently facilitated the extinction and decreased the reinstatement of METH-induced CPP. CONCLUSION: Brain D3 receptors are critically involved in the reward and psychomotor-stimulating effects of METH. Thus, YQA14 deserves further study as a potential medication for METH addiction.
AIM: We have reported that a selective dopamine D3 receptor antagonist YQA14 attenuates cocaine reward and relapse to drug-seeking in mice. In the present study, we investigated whether YQA14 could inhibit methamphetamine (METH)-induced locomotor sensitization and conditioned place preference (CPP) in mice. METHODS: Locomotor activity was monitored in mice treated with METH (1 mg/kg, ip) daily on d 4-13, followed by a challenge with METH (0.5 mg/kg) on d 21. CPP was examined in mice that were administered METH (1 mg/kg) or saline alternately on each other day for 8 days (METH conditioning). YQA14 was injected intraperitoneally 20 min prior to METH or saline. RESULTS: Both repetitive (daily on d 4-13) and a single injection (on the day of challenge) of YQA14 (6.25, 12.5 and 25 mg/kg) dose-dependently inhibited the acquisition and expression of METH-induced locomotor sensitization. However, repetitive injection of YQA14 (daily during the METH conditioning) did not alter the acquisition of METH-induced CPP, whereas a single injection of YQA14 (prior to CPP test) dose-dependently attenuated the expression of METH-induced CPP. In addition, the repetitive injection of YQA14 dose-dependently facilitated the extinction and decreased the reinstatement of METH-induced CPP. CONCLUSION: Brain D3 receptors are critically involved in the reward and psychomotor-stimulating effects of METH. Thus, YQA14 deserves further study as a potential medication for METH addiction.
Authors: Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish Journal: J Neurosci Date: 2012-01-25 Impact factor: 6.167
Authors: Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner Journal: Neuropsychopharmacology Date: 2005-10-05 Impact factor: 7.853
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Anna-Rose Childress; Millard Jayne; Yeming Ma; Christopher Wong Journal: J Neurosci Date: 2006-06-14 Impact factor: 6.167
Authors: Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner Journal: Psychopharmacology (Berl) Date: 2007-11-06 Impact factor: 4.530
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Anna-Rose Childress; Millard Jayne; Yeming Ma; Christopher Wong Journal: Neuroimage Date: 2007-10-11 Impact factor: 6.556
Authors: Tracey A Larson; Madeline C Winkler; Jacob Stafford; Sophia C Levis; Casey E O'Neill; Ryan K Bachtell Journal: Psychopharmacology (Berl) Date: 2018-11-23 Impact factor: 4.530
Authors: Sun Mi Gu; Hye Jin Cha; So Woon Seo; Jin Tae Hong; Jaesuk Yun Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-08-01 Impact factor: 3.000
Authors: Yang Lv; Rong-Rong Hu; Manyi Jing; Tai-Yun Zhao; Ning Wu; Rui Song; Jin Li; Gang Hu Journal: Acta Pharmacol Sin Date: 2018-09-17 Impact factor: 6.150
Authors: Justin R Yates; Hunter L Campbell; Lauren L Hawley; Matthew J Horchar; Joy L Kappesser; Makayla R Wright Journal: Drug Alcohol Depend Date: 2021-05-26 Impact factor: 4.852